Welcome to our dedicated page for JanOne news (Ticker: JAN), a resource for investors and traders seeking the latest updates and insights on JanOne stock.
JanOne Inc. (Nasdaq: JAN) is a pioneering clinical-stage pharmaceutical and biopharmaceutical company headquartered in Las Vegas, Nevada. Since its inception in 1976, JanOne has been committed to developing innovative, non-addictive pain relief therapies to address severe pain conditions and ultimately reduce dependency on opioid prescriptions. Through its lead candidate Jan101, a slow-release formulation of sodium nitrite, the company targets the treatment of Peripheral Artery Disease (PAD). Another promising drug, Jan123, focuses on treating Complex Regional Pain Syndrome (CRPS), a debilitating orphan disease lacking FDA-approved treatments.
The company's mission is significantly impactful in light of the ongoing opioid crisis, one of the deadliest epidemics in U.S. history. JanOne’s unique approach targets the root causes of pain, providing non-opioid alternatives that could potentially mitigate the risks associated with opioid abuse.
In recent developments, JanOne has filed an international patent application for low dose naltrexone to treat chronic pain, which could bolster its intellectual property portfolio and help patients worldwide. The company has also made significant strides in the fintech sector by acquiring ALT 5 Sigma Inc., a blockchain financial technology provider, diversifying its operations into the digital asset market.
JanOne operates through two main segments: Biotechnology and fintech (through its subsidiary ALT 5). ALT 5 offers innovative blockchain-powered technologies like ALT 5 Pay and ALT 5 Prime, facilitating crypto-currency payments and electronic over-the-counter trading of digital assets.
JanOne has received accolades for its research, such as the
JanOne (NASDAQ: JAN) announced a successful pre-IND meeting with the FDA on April 18, 2023, regarding Jan123, a low dose naltrexone aimed at treating complex regional pain syndrome (CRPS). This rare disease causes severe pain and has no current cure. The FDA's feedback gives JanOne a pathway for submitting a New Drug Application under the 505(b)(2) designation. Key discussion points included preclinical toxicology and clinical implementation, which are crucial for progressing Jan123 towards formal approval. Both JanOne's Chief Medical Officer and CEO expressed optimism about the therapeutic potential of Jan123 and its role in addressing the opioid crisis. The company emphasizes its commitment to innovative pain management solutions.
JanOne (Nasdaq: JAN), represented by Dr. Amol Soin, will present at the Appalachian Region Spine and Pain Meeting on April 15, 2023, discussing innovation in pain medicine and the company’s drug development programs. JanOne focuses on non-opioid treatments for pain management, introducing two late-stage drug candidates: JAN 101, aimed at treating peripheral artery disease and diabetic neuropathy, and JAN 123, a low-dose naltrexone for Complex Regional Pain Syndrome, which received orphan drug status from the FDA. Dr. Soin aims to highlight the need for effective pain management solutions amid the opioid crisis, which underscores JanOne's commitment to developing non-addictive medication options. The meeting will serve as a platform to engage physicians seeking alternatives to opioids.
JanOne, a biopharmaceutical company on Nasdaq (JAN), announced the appointment of John N. Bonfiglio, PhD, as the interim president of its subsidiary, JanOne Biotech. His extensive background in leading successful biotech firms includes raising over
FAQ
What is the current stock price of JanOne (JAN)?
What is the market cap of JanOne (JAN)?
